Navigation Links
BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
Date:5/28/2009

TURKU, Finland, May 28 /PRNewswire/ -- BioCis Pharma Ltd., a privately-held drug development company with its headquarters in Turku, Finland, has started Phase I clinical testing of ProtoCure(TM) intravesical instillation solution, a novel anti-cancer drug for urinary bladder cancer. ProtoCure is based on a new mechanism of action discovered and developed by BioCis Pharma which effectively prevents cancer growth and proliferation locally.

The open-label, dose-escalating study is designed to evaluate the safety, tolerability and pharmacokinetics of the locally administered (into the bladder) product in a total of 22 patients with primary or recurrent non-muscle invasive bladder cancer and it is expected to be well tolerated.

"We are pleased to advance to clinical testing with the ProtoCure instillation solution," says Lasse Leino, CEO of BioCis Pharma. "It is our first oncology product to reach this important milestone and follows the initiation of two phase 2a studies with our leading anti-inflammatory product in patients with inflammatory skin disorders that we recently announced. The ProtoCure cancer drug holds great promise for patients suffering from superficial bladder cancer. We are committed to take the product quickly to more extensive clinical efficacy testing after this preliminary safety study. We expect to get results from this study by the first quarter of 2010."

Bladder cancer is the fourth most common cancer in men and tenth among women. In addition, the recurrence rate is high, being almost 70 % in patients with the non-invasive form of the cancer, where the malignancy is typically found in the surface layers of the bladder. Non-invasive bladder cancer is treated by urologists using local surgery and intravesical drug therapy administered directly into the bladder. Existing drug therapies often have undesirable side effects and limited efficacy.

BioCis Pharma Lt
'/>"/>

SOURCE BioCis Pharma Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
2. TRACON Pharmaceuticals Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
3. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
4. New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
5. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
6. PARI Pharmas Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS
7. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
8. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
9. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
10. Tris Pharma Announces Acceptance of Its First Two NDAs
11. Addrenex Pharmaceuticals Expands Product Pipeline by Licensing New Drug to Treat Narcolepsy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  STAAR Surgical Company (NASDAQ: STAA ) ... delivery systems for the eye, today announced that management will ... New York Palace Hotel on Wednesday, September 3 at 7:15 ... President and CEO will offer a general overview of the ... be joined by Steve Brown , CFO, and ...
(Date:8/28/2014)... , Aug. 28, 2014 Synthetic Biologics, ... anti-infective biologic and drug candidates targeting specific pathogens ... Diosynth Biotechnologies UK Limited (Fujifilm), announced today confirmation ... cGMP manufacturing of SYN-004, Synthetic Biologics, proprietary oral ... difficile ( C. difficile ) infections. ...
(Date:8/28/2014)... -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ... trials evaluating the use of collagenase clostridium histolyticum (CCH) for ... with a palpable cord will be presented at the upcoming ... Surgery of the Hand (ASSH) being held in ... (CCH) is a biologic approved in the U.S., EU, ...
Breaking Medicine Technology:STAAR Surgical To Present At The Baird 2014 Health Care Conference 2Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 2Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 3Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 4Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile 5Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 2Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 3Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 4Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 5Auxilium Pharmaceuticals, Inc. To Present CCH Data For Concurrent Treatment Of Multiple Dupuytren's Cords At ASSH Annual Meeting 6
... Medical Systems Ltd. (NASDAQ: DHRM) ("Dehaier" or ... assembly, marketing and sale of medical devices and ... plans to release its financial results for the ... 31, 2011 on Monday, March 19, 2012, after the stock ...
... Timothy C. Tyson, Aptuit Chairman, announced that effective immediately, ... Operating Officer of Aptuit LLC. Following the recent sale ... has been promoted from his previous position at Aptuit ... Needleman is responsible for all day-to-day operations of the ...
Cached Medicine Technology:Dehaier Medical Systems Schedules 2011 Fourth Quarter and Full Year Financial Results and Conference Call 2Dehaier Medical Systems Schedules 2011 Fourth Quarter and Full Year Financial Results and Conference Call 3Aptuit LLC Names Stuart E. Needleman as President and Chief Operating Officer 2
(Date:8/28/2014)... (PRWEB) August 28, 2014 Edvance360 ... the top ten tools for online teaching, as well ... for Best Course or Learning Management System, announced that ... Academy, Typewell, Dialysis Treatment Center of America, Metis Leadership ... and HMG Plus, to the user community. , ...
(Date:8/28/2014)... 2014 Every year, cataracts affect over 22 ... the leading cause of blindness in the world. Characterized by ... the iris, cataracts are estimated to affect an additional 30 ... aging population. Cataracts are just one of the many conditions ... Tracy of Carlsbad Eye Care screens patients for a number ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Labor Day ... the beach and those last glorious glimpses of summer. ... patients are planning on spending their long weekend recovering ... Sadati, a board certified facial plastic and reconstructive surgeon ... patients have taken advantage of their holiday weekends to ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Atlantic Information ... of the latest addition to its Management Insight Series, ... a Major Patient Privacy/Security Risk . The new report ... manage the risks associated with portable electronic devices, and ... federal requirements. , With expert advice on how to ...
(Date:8/28/2014)... 2014 In the healthcare industry, there ... struggle with: How can the overall quality of patient ... of the healthcare industry tackles this question, and has ... job satisfaction and the quality of patient care. ... in “ Organizational Factors related to Improving Quality of ...
Breaking Medicine News(10 mins):Health News:Edvance360 Continues to Experience Growth in Corporate, K-12, Health, and Non-Profit Sectors 2Health News:Cataract Awareness Month an Opportunity to Focus on Vision Care and Ocular Health 2Health News:Newport Beach Facial Plastic Surgeon, Dr. Kevin Sadati Announces a Patient Trend of Scheduling Cosmetic Surgery Procedures over Long Holiday Weekends 2Health News:Newport Beach Facial Plastic Surgeon, Dr. Kevin Sadati Announces a Patient Trend of Scheduling Cosmetic Surgery Procedures over Long Holiday Weekends 3Health News:Newport Beach Facial Plastic Surgeon, Dr. Kevin Sadati Announces a Patient Trend of Scheduling Cosmetic Surgery Procedures over Long Holiday Weekends 4Health News:New Report Offers Best Practices for Avoiding the Patient Privacy/Security Risks Posed by Mobile Devices 2Health News:New Healthcare Study Explores Strategies for Improving Patient Care 2Health News:New Healthcare Study Explores Strategies for Improving Patient Care 3Health News:New Healthcare Study Explores Strategies for Improving Patient Care 4
... July 7 HealthSouth,Corporation (NYSE: HLS ) ... to acquire a 30-bed inpatient rehabilitation unit at ... is currently owned by Columbia,Medical Center of Arlington ... operations will relocate to HealthSouth Rehabilitation,Hospital of Arlington., ...
... recycling benefits our planet; and now new research suggests ... cancer. Scientists at Stanford University have identified a molecule ... cells. The research, published by Cell Press in the ... , may drive treatment strategies for cancer in an ...
... and geographic boundaries are some of the challenges that ... for a possible influenza pandemic, according to a new ... who are leading planning efforts for an influenza outbreak ... defined by political lines," said George Avery, an assistant ...
... Pa., July 7 Digestive Care, Inc. (DCI),announced today ... New Drug,Application ("NDA") for PANCRECARB(R) (pancrelipase), used in the ... and Drug,Administration ("FDA"). The FDA has granted the product ... used to treat EPI for over,a decade and we ...
... Satisfaction Rate 94% - 100%, ARLINGTON HEIGHTS, ... after an elective mastectomy are satisfied with,their decision, ... do it,again, reports a study in July,s Plastic ... American Society of Plastic Surgeons,(ASPS). In addition, breast ...
... Ill. Women who have breast reconstruction after an ... complication rates and 98 percent would do it again, ... Surgery , the official medical journal of the American ... reconstruction after preventive mastectomy was as safe as or ...
Cached Medicine News:Health News:HealthSouth To Acquire Rehabilitation Unit at Medical Center of Arlington 2Health News:HealthSouth To Acquire Rehabilitation Unit at Medical Center of Arlington 3Health News:Can recycling be used to treat cancer? 2Health News:Political borders, health-care issues complicate pandemic planning 2Health News:Political borders, health-care issues complicate pandemic planning 3Health News:Digestive Care, Inc. Announces the Filing of the First Module of NDA Submission for PANCRECARB(R) (pancrelipase) 2Health News:98% of Elective Mastectomy Patients Would Have Reconstruction Again, Says ASPS Study 2Health News:98 percent of elective mastectomy patients would have reconstruction again, says ASPS study 2
... is ideal for all liquid handling applications ... operating buttons, and various dispensing techniques such ... make this a lab favorite. It intuitively ... pipette without any adverse effects on the ...
Single channel module for Finnpipette Biocontrol - Universal handle sold separately...
... the ease and comfort you've come to expect ... in clinical trials agreed that the BD Lancet ... settings allow you to choose the best lancet ... lancets, the device also helps eliminate the "vibrations" ...
... StaRRsed-III is a system that measures ... samples. This rate may be relevant ... The sedimentation rate is measured in ... typically used in high-volume settings such ...
Medicine Products: